Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
21 nov. 2023 08h01 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
15 nov. 2023 16h02 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Announces Departure of Board Member
13 nov. 2023 16h02 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx to Participate at the Jefferies London Healthcare Conference
10 nov. 2023 08h05 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
06 nov. 2023 08h00 HE
|
Ardelyx, Inc.
XPHOZAH is the first and only FDA approved phosphate absorption inhibitor Best-in-class patient services programs support patient access and affordability for XPHOZAH patients WALTHAM, Mass., Nov. ...
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
03 nov. 2023 08h00 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
31 oct. 2023 07h00 HE
|
Ardelyx, Inc.
Continued successful launch of IBSRELA, with Q3 net sales revenue of $22.3 million; Company currently expects 2023 full year IBSRELA U.S. net sales revenue to be $76 to $78 million XPHOZAH®...
Ardelyx, Inc. Reports Employment Inducement Grants
30 oct. 2023 17h42 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
23 oct. 2023 08h07 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
18 oct. 2023 16h02 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...